Craig-Hallum raised the firm’s price target on Pulmonx to $20 from $18 and keeps a Buy rating on the shares. The firm notes Pulmonx ended the year on a high note, as Q4 sales exceeded Street estimates and the newly issued 2024 guidance surpassed expectations.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LUNG:
- Pulmonx Announces Executive Leadership Transition and Board Changes
- Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer
- Pulmonx Reports Fourth Quarter and Full Year 2023 Financial Results
- Pulmonx to Report Fourth Quarter and Full Year 2023 Financial Results on February 21, 2024
